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Recent studies regarding mucosal drug delivery indicate that nanosystems with surface-available 
polyethylene glycol (PEG) are able to penetrate mucus barrier, assure closer contact with the 
epithelium, and improve drug delivery to vagina. In the present work, we developed the mucus-
penetrating PEGylated liposomes containing interferon alpha-2b (IFN α-2b), destined to provide 
localized therapy for human papilloma virus (HPV) vaginal infections. The PEGylated liposomes 
were of a mean size of 181 ± 8 nm, bearing a negative zeta potential of – 13 mV and an 
entrapment efficiency of 81 ± 10 %. In vitro release experiments on model membrane showed a 
nearly non-existent IFN α-2b release from both the control and liposomally-associated IFN α-2b. 
However, the ex vivo penetration studies performed on the vaginal tissue obtained from pregnant 
sheep, showed the clear elevated IFN α-2b penetration from PEGylated liposomes as compared to 
the control. Furthermore, mucin studies confirmed the absence of interaction between the PEG-
modified liposomes and mucin, confirming their ability to penetrate mucus and reach the deeper 
epithelium. The system holds a promise in improving topical delivery of IFN α-2b through 
enhanced efficacy of local anti-viral therapy.  
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Human papilloma virus (HPV) infections, which are responsible for genital warts and transmitted 
via mucosal surfaces, are one of the most common sexually transmitted diseases (STDs) [1]. 
Although HPV infections are common in both genders, due to the physiology and anatomy of 
vagina, women are more prone to the infections and the efficacy of the treatment remains limited. 
It is estimated that 80 % of all sexually active women will acquire HPV infection by the age of 50 
[2]. Some of the HPV infections may spontaneously resolve in younger women; however, the 
high-risk HPV infections are persistent among women over the age of 30 and often lead to 
cervical pre-cancerous lesions. Cervical cancer is the second most common cancer in women and 
the fifth most common cancer overall [1].  
Currently available anti-viral therapies mainly target the visible lesions failing to eliminate the 
virus with the recurrence rate of up to 90 % [3]. For treatment of visible lesions, intralesional 
injections of interferon alpha-2b (IFN α-2b) have been an optional treatment; however, in this 
treatment option the patients suffer from the pain due to direct injections into each region and 
severe side effects due to systemic exposure. Moreover, only five visible lesions can be treated in 
a single session [1]. The treatment is not suitable for latent or subclinical infections and a more 
sophisticated non-invasive approach is desirable.  
The potential of topical treatment of genital warts was one of the first studies reporting vaginal 
applications of liposomal drugs. In a preliminary clinical testing, topical treatment with liposomal 
IFN α-2b achieved complete resolution of cervical lesions in a female patient at the end of 
therapy [4]. PEGylation of IFN α-2b can provide a prolonged half-life and a shift of distribution 
towards infected tissues due to increased capillary permeability, thereby improving efficacy and 




increase its stability and alter its pharmacokinetics, two issues which often limit the success of 
IFN therapy [6,7]. 
To achieve an efficient local delivery to mucosal tissue, the penetration into/through the mucus 
mesh, uniform distribution of drug into the underlying tissue and sufficiently high drug 
concentration are required. Mucus, a physical barrier in the form of an adhesive gel that stick to 
most particles, prevents most of the foreign particles from penetrating into the epithelium surface. 
Moreover, mucus exhibits the ability to form an unstirred layer of mucus adjacent to epithelial 
surfaces not affected by the shearing actions [8]. To penetrate this unstirred layer, nanosystems 
should be able to diffuse through it in a manner similar to viruses. Viruses can overcome this 
barrier and cause infection rather easily [9]. Therefore, biomimicking the viral properties might 
be a promising approach. 
 
Polyethylene glycol (PEG) is an uncharged hydrophilic polymer widely applied in 
pharmaceutical formulations, including those for topical vaginal therapy. When used as a coating 
material, PEG enables nanoparticles to diffuse through vaginal mucus by eliminating the 
adhesive interactions between the nanoparticles and mucus [9,10], assuring a closer contact to the 
vaginal epithelium, and enabling improved drug effectiveness. The synergy between the 
properties of liposomes as a protective carrier for sensitive biologicals and the mucus-penetrating 
properties of PEG available on liposomal surface, enables the development of a vaginal drug 





In the present study, we developed liposomal carriers containing IFN α-2b with surface-available 
low molecular weight PEG (MW of 2000) as a mucus-penetrating delivery system able to 
distribute IFN α-2b to vaginal mucosa assuring improved localized therapy. 
 
2. Materials and Methods 
2.1. Materials 
Lipoid S 100 (PC, soybean lecithin, > 94 % phosphatidylcholine) was a gift from Lipoid GmbH, 
Ludwigshafen, Germany; methoxy poly (ethylene glycol)-modified lipids (mPEG 2000) was 
from the same manufacturer. IntronA® 50 MIU/mL injection fluid in multiple dose pen was the 
product of MSD AS, Drammen, Norway. Acetic acid, bovine serum albumin, calcium hydroxide, 
chitosan (low MW, Brookfield viscosity 20.000 cps, degree of deacetylation 92 %), cholesterol, 
fructose, glycerol, mucin from porcine stomach (type III, bound sialic acid 0.5 % - 1.5 %, 
partially purified), potassium phosphate monobasic, Sephadex® G-50, Triton® X-100 and zinc 
chloride were all purchased from Sigma-Aldrich Chemie GMbH, Steinheim, Germany. Di-
sodium hydrogen phosphate, sodium dihydrogen phosphate monohydrate, potassium chloride and 
titriplex (ethylenedinitrilotetraacetic acid disodium salt dihydrate) were obtained from Merck 
KGaA, Darmstadt, Germany. Glucose, lactic acid, polysorbatum, potassium hydroxide, sodium 
citrate dihydrate and urea were the products of NMD, Oslo, Norway. Ammonium acetate, 
magnesium chloride and potassium chloride was the product of VWR International BHD Prolab, 
Leuven, Belgium. ELISA kit was purchased from Bio-Techne, Abingdon, UK. 
 




The PEGylated liposomes were prepared by the conventional film method as previously 
described [11]. Briefly, cholesterol (10 mg), mPEG 2000 (36.3 mg) and PC (200 mg) were 
dissolved in methanol and chloroform (1:1, v/v) in a round bottom flask. Solvents were removed 
through evaporation (Büchi rotavapor R-124 with vacuum controller B-721, Büchi Vac® V-500, 
Büchi Labortechnik, Flawil, Switzerland) for 2 hours at 50 mm Hg and 50 °C. The remaining 
film was flushed with nitrogen to assure no residual solvents. The lipid film was then re-
suspended in 5 mL of IFN α-2b solution from IntronA® 50 million IU/mL (MIU/mL) injection 
fluid and Intron A buffer (pH 7.4; 7.5 g/L NaCl, 1.8 g/L NaH2PO4, 1.3 g/L Na2HPO4, 0.1 g/L 
EDTA and 0.1 g/L Polysorbate 80) resulting in a final IFN α-2b concentration of 2 MIU/mL. 
Similar procedure was applied in the preparation of empty liposomes; the lipid film was re-
suspended in Intron A buffer free of IFN α-2b. Liposomal suspensions were kept in a refrigerator 
(4 - 8˚C) for at least 12 hours prior to further use. 
 
2.3. Vesicle size reduction 
Extrusion through polycarbonate membranes (Nuclepore Track-Etch Membran, Whatman House, 
Maidstone, UK) [12] was employed in the reduction of liposomal size. The extrusion was 
performed stepwise through 0.8, 0.4 and 0.2 µm pore size filters, respectively. Three extrusions 
were performed on each pore size filters. Extruded liposomes were kept in a refrigerator (4-8 °C) 
for at least 6 hours prior to characterization and further experiments. 
 




The particle size distribution of liposomal samples was measured by photon correlation 
spectroscopy (Submicron particle sizer model 370, Nicomp, Santa Barbara, California, USA) 
according to Jøraholmen et al. [11]. Analyses were run in a vesicle mode and the particle 
intensity of approximately 200-350 kHz. The data were calculated as intensity weighted 
distribution from three measuring cycles (each with a run time of 10 min).  
 
2.5. Zeta potential measurements 
Zeta potential determinations were performed on a Malvern Zetasizer Nano ZS (Malvern, 
Oxford, UK). Prior to measurement, the measurement cells were properly cleaned with ethanol 
and filtrated water, respectively. To obtain a suitable count rate, the liposomal suspensions 
samples were diluted in filtrated water to adequate concentrations (typically 1:20, v/v) before 
loading the sample into the cells [12]. Three parallels were determined for each sample 
measurement. 
 
2.6. IFN α-2b entrapment 
Liposomally-entrapped IFN α-2b and free drug were separated by the size-exclusion gel 
chromatography. Sephadex® G-50 in Intron A buffer (75 mg/mL) was left to swell overnight (at 
4-8 °C). The gel was packed in a column (50 mL) and flushed with Intron A buffer. The 
stationary phase measured 65 cm
3
. Liposomal sample containing IFN α-2b (1.2 mL) was applied 
on top of the column and 100 fractions of 1 mL was collected. Eluate time was 1.8 mL/min. The 




An enzyme-linked immunoassay kit (VeriKine™ Human IFN α-2b Multi-Subtype ELISA kit) 
was used for the quantification of IFN α-2b. Aliquots of the samples were diluted in 0.1 % Triton 
(Triton X-100 in Intron A buffer) to disintegrate liposomes and further diluted to suitable 
concentrations with Intron A buffer. The procedure was performed according to manufacturer’s 
instructions. In brief, standards and diluted samples were added to microplate coated with IFN α-
2b antibodies. Diluted antibody solution, diluted horseradish peroxidase and tetramethyl-
benzidine substrate were added step-wise after 1 hour incubation. Finally, the reaction-
terminating solution was added after 15 min incubation. Amount of liposomally-associated IFN 
α-2b was determined by UV spectrophotometry at 450 nm (Microtitre plate reader; Spectra Max 
190 Microplate, Spectrophotometer Molecular devices, Sunnyvale, California, USA). 
 
2.7. In vitro mucin-binding 
The binding of PEGylated liposomes to mucin was determined to confirm that the delivery 
system is not mucoadhesive. The test was performed as previously described [12]. Briefly, 
aliquots (1 mL) of empty PEGylated, non-coated and 0.1 % (w/v) chitosan-coated liposomes 
(prepared according to Jøraholmen et al. [11]) were added to an equal volume of mucin 
suspension (400 μg/mL) in phosphate buffer (pH 7.4) and acetate buffer (pH 4.6), respectively. 
Incubation at room temperature for 2 hours was followed by ultracentrifugation at 216 000 g for 
1 hour, at 10 °C (Optima LE-80; Beckman Instruments, Palo Alto, California, USA). Free mucin 
and four aliquots (200 μL) from the supernatant were transferred to a microtitre plate (Costar® 
UV 96-well plate with UV transparent flat bottom, Acrylic, Costar®, Corning, New York, USA) 




Spectrophotometer Molecular devices, Sunnyvale, California, USA). Mucin-binding capacity 
was calculated based on Naderkhani and colleagues [13]. The experiments were performed in 
triplicates. 
 
2.8. In vitro release 
The in vitro IFN α-2b release experiment was performed on the Franz cell manual diffusion 
system (Perme Gear Ink, Diffusion cells and Systems, Hellertown, USA) as previously described 
[11]. The system and accessories were thoroughly cleaned with methanol, demineralized water 
and distilled water, respectively, prior to experiment. The heating circulator (Julabo 
Laboratechnik, F12-ED, Seelback, Germany) was set to maintain a temperature of 37 °C. The 
acceptor chambers with a volume of 12.1 mL were completely filled with acetate buffer (pH 4.6; 
77.1 g CH3COONH4, 70 mL glacial acetic acid and distilled water up to 1000 mL). Polyamide 
membrane (Sartorius polyamide membrane, 0.2 μm pore size, Sartorius AG, Gröttingen, 
Germany) was cut to a suitable size (diffusion area of 1.77 cm
2
) and fixed between the donor and 
acceptor chambers. The IFN α-2b content in all included samples was determined (ELISA) prior 
to the experiment to prepare a control solution (IFN α-2b in Intron A buffer) containing similar 
drug concentration. Liposomal samples and controls (550 µL), as well as vaginal fluid simulant 
(VFS) (pH 4.6; 3.51 g/L NaCl, 1.40 g/L KOH, 0.222g/L Ca(OH)2, 0.018 g/L bovine serum 
albumin; 2 g/L lactic acid, 1g/L acetic acid, 0.16 g/L glycerol, 0.4 g/L urea and 5 g/L glucose; 50 
µL) [14] were added in the donor cells and the system was closely sealed. Sampling from 
acceptor chamber (500 µL) was done after 1, 2, 4, 6 and 8 hours and the samples withdrawn from 




concentrations in the withdrawn samples, remaining in the donor cells and retained in the 
polyamide membrane were determined with ELISA kit and UV spectrophotometry as described 
above. The experiments were performed in triplicates. 
 
2.9. Preparation of vaginal tissue 
Vaginal tissue from pregnant sheep was acquired from the Laboratory Animal Centre, University 
of Oulu, Finland. The experiments were performed according to the guidelines of the National 
Animal Experiment Board in Finland. The vaginal tissue was cautiously dissected and removed 
from the underlying tissue, cleaned and moistened with physiological solution (pH 7.4), then 
packed in a clinging film before the tissues were frozen (-20 °C). Prior to the experiments, the 
tissue was left to defrost in phosphate buffer (pH 7.4) at room temperature for at least 1 hour. We 
have earlier reported that no significant differences were observed in using fresh or snap-frozen 
vaginal tissue samples and that the barrier properties of the fresh vaginal tissue and frozen and 
thawed tissue are similar [11]. 
 
2.10. Ex vivo penetration 
The experiment was performed on the Franz cell manual diffusion system as described above. 
Briefly, the acceptor chambers were filled up with phosphate buffer (pH 7.4, 8 g/L NaCl, 0.19 
g/L KH2PO4, and 2.38 g/L Na2HPO4). Sheep vaginal tissue was defrosted, cut to appropriate size 
(1.77 cm
2
) and fixed between donor cell and acceptor chamber. Samples and controls (550 µL), 
with similar amount of IFN α-2b, as well as VFS (50 µL) were added in the donor cells and the 




6 and 8 hours and withdrawn volumes replaced by an equal volume of phosphate buffer. Amount 
of IFN α-2b in the collected samples, remaining in the donor cells and retained in the vaginal 
tissue were determined with ELISA kit and UV spectrophotometry as described above. The 
experiments were performed in triplicates. 
 
 
2.11. Stability of PEGylated liposomes in the presence of biological fluids 
Human semen simulant was prepared according to Owen and Katz [15]. Briefly, the solution 2 
(101 mg CaCl2 x 2H2O, 15.13 mL H2O), the solution 3 (92 mg MgCl2 x 6H2O, 15.13 mL) and 
solution 4 (34.4 mg ZnCl2, 15.13 mL H2O) were added into the solution 1 (5.6 mL 0.123 M 
NaH2PO4 x H2O, 49.14 mL 0.123 M Na2HPO4, 813 mg sodium citrate dehydrate, 90.8 mg KCl, 
88.1 mg KOH, 272 mg fructose, 102 mg glucose anhydrase, 62 mg lactic acid, 45 mg urea, 5.04 
mg bovine serum albumin). The solutions were mixed and pH was adjusted to 7.7 with sodium 
hydroxide solution. 
Aliquots (500 µL) of liposomal suspensions containing IFN α-2b (free of unentrapped IFN) were 
mixed with human semen simulant (500 µL) and VFS (50 µL), and incubated at room 
temperature for 2 hours. The leaked (free) IFN α-2b was separated from liposomally-associated 
IFN α-2b by size-exclusion gel chromatography (as described in 2.6). Quantification of IFN α-2b 
in the fractions was performed with ELISA kit and UV spectrophotometry as described above. 
 




For the comparison of two means, statistical significance was determined using the student's t-
test. A p-value less than 0.05 was considered statistically significant. 
 
3. Results and Discussion 
Interferons are widely used clinically relevant biologicals. Their anti-viral, anti-proliferative and 
immunomodulatory effects have been confirmed and several subtypes are already clinically 
approved for various indications [16]. IFN exhibits anti-viral effect on HPV-infected cells, and is 
of a great interest in the search for therapeutic use in the treatment of HPV infections [1]. The 
short circulation time and unwanted effects on the non-target tissues following systemic 
administration limit its wider utilization as biological. Topical treatment option assures drug 
delivery directly to the site of infection and increased efficiency at lower doses, reduced adverse 
effects due to decreased systemic levels and a more adequate treatment even for non-visible 
lesions. Currently, the lack of suitable delivery systems is the main challenge to successful HPV 
infection treatment. With an optimized formulation, that enables an efficient local delivery to 
mucosal tissue and provides increased stability of IFN, these limitations can be overcome [17]. 
 
3.1. Liposomal characteristics 
The effectiveness of local drug delivery at the vaginal site is determined by the physicochemical 
characteristics of the delivery system. The vesicle size affects the ability to fit within the mucin 
pores, while the particles surface charge and properties establish the potential attraction or 




aiming for local therapy at the mucosal site is controlling the surface properties, particle size and 
surface charge [19]. The protective mucus layer traps the foreign particulates and acts on their 
removal [20]. Biomimetic approach in design of novel delivery systems for IFN can offer the 
necessary improvements in the efficacy of localized vaginal therapy. Polyethylene glycol (PEG) 
shields the nanoparticles from adhesive interactions with mucus [21]. Sufficient number of PEG 
molecules available on the vesicle surface effectively minimizes the adhesive interactions 
between vesicles and mucus, creating the mucus-penetrating particles that can efficiently 
penetrate the human mucus [10,22]. The optimal PEG content and density on the particle’s 
surface were studied to optimize the penetration potential and system’s stability in vaginal 
environment. Xu and colleagues [20] suggested that at least 5 % PEG (wt) was required to assure 
complete shielding and avoid mucoadhesion. The surface density and molecular weight of PEG 
directly affect the particle transport, and literature indicates that dense coating with low 
molecular weight PEG increases the transport rate through the mucus significantly [23]. We used 
targeted PEG content of 14 % (wt), which is expected to provide surface PEG content of over 7 
% (wt), as reported by Hanes group [20] for biodegradable poly(lactic-co-glycolic acid) 
nanoparticles-bearing PEG. PEG in this concentration is expected to be in the dense brush 
conformation [20]. The same group [24] further examined the diffusion of liposome-based 
mucus-penetrating particles in human cervicovaginal mucus by magnetic resonance imaging and 
suggested that 7 % (molar) was an optimal coating concentration for theranostic purposes. By 
modifying liposomal surface with low molecular weight PEG we aimed to develop an advanced 
carrier for IFN α-2b for the local therapy at vaginal site.  
Uniform distribution deep into the folded vaginal epithelium over the cervicovaginal mucosa is a 




Although there is no consensus regarding the effect of nanocarrier size on the mucosal targeting 
at vaginal site, it is known that small particles will easily be trapped in the mucus mesh while 
larger particles will be retained on the mucus surface. Viruses with diameters between 30 and 200 
nm are able to reach and infect the vaginal mucosa efficiently [18]. However, Lai and colleagues 
[23] showed that larger particles (200-500 nm) densely coated with PEG are more rapidly 
transported through fresh undiluted human mucus than the corresponding particles of smaller size 
(100 nm). Based on the above, in our study, we aimed for vesicles in size range of around 200 
nm. The vesicle size of our PEGylated liposomes was close to the targeted size range (Table 1). 
We reported earlier [12] that the extrusion as a size reduction method can be readily applied to 
obtain vesicles in desired size range with favourable polydispersity. Our liposomes exhibited 
rather narrow size distribution with low PI (Table 1). 
 
Table 1: Characteristics of PEGylated liposomes containing IFN α-2b (n = 3). 
 
Considering optimal mucus-penetration, a nearly neutral vesicle surface charge is desirable to 
assure mucus-penetrating properties [23]. However, it is also suggested that a negatively charged 
component present in the liposomal bilayer responsible for negative charge on the vesicle surface 
is beneficial for a stable association and will improve IFN α-2b entrapment and prevent drug 
leakage from the liposomes [6]. The optimized formulation should be a balance between the drug 
load and surface characteristics of the vesicles. Our PEGylated liposomes exhibited a slightly 




Even if the carrier system exhibits desired mucus-penetrating properties, it is very important that 
the drug load is sufficient to achieve desired therapeutic response. We were able to achieve rather 
high entrapment efficiency of 81 % (Table 1). This is in accordance with literature data [7,25-27]. 
Compared to other lipid-based delivery systems, such as the biphasic IFN-containing vesicles for 
topical therapy of HPV infections, the entrapment efficiency in our vesicles was in the same 
range [28]. However, both the vesicle size and size distribution of the biphasic vesicles were 
considerably larger (1000-1100 nm) compared to our PEGylated liposomes (181 ± 8 nm), 
suggesting that even vesicles of smaller sizes can carry sufficient drug load. In addition, it is 
known that by incorporating IFN α-2b in liposomal formulations, an increase in its stability and 
positive alteration of its pharmacokinetics can be obtained [6,7]. The size and size distributions of 
our vesicles, as well as the presence of PEG on vesicle surfaces indicate that the vesicles should 
remain stable in respect to both aggregation and potential loss of originally encapsulated IFN α-
2b.  
 
3.2. Mucus-penetrating properties 
Mucus immobilizes particles by hydrophobic and electrostatic interactions as well as hydrogen 
bonding [29]. Mucin fibers in the healthy human vaginal mucus are negatively charged and 
reported to have a diameter of approximately 340 nm [10]. Mucus properties are affected by the 
environmental changes, such as the changes in pH due to vaginal infections and the viscosity of 
vaginal fluid. When exposed to bacterial vaginosis, a reduction in the viscosity of vaginal fluid 
causes the reduced barrier properties and increased risk of infection [30]. It is further suggested 




increasing the average pore size of mucin fibers. This can provide easier access for foreign 
particles to vaginal mucosa, including the pathogens and other potentially toxic nanomaterials, 
due to the impaired mucus barrier. However, the limited literature data indicate that the mucus-
penetrating particles did not exhibit similar effect on the cervicovaginal mucus [21]. 
 
It was originally proposed that PEGylation of nanoparticles leads to increased mucoadhesiveness, 
and that PEG exhibits mucoadhesive properties that are expressed by the interpenetrating 
polymer network effects between PEG chains and the mucus mesh [31-33]. Recent studies, 
however, have demonstrated that PEG-surface modified nanoparticles minimize mucoadhesion 
and are able to effectively penetrate the mucus enabling closer contact between the nanosystem 
and the underlying epithelium [9,10,22,34]. To achieve the mucoinert surfaces a fine-tuning of 
the interactions between particles and mucus is required. Coating of particles with a dense layer 
of low molecular weight PEG effectively reduces the hydrophobic interactions, hydrogen 
bonding interpenetrating polymer network effects below the threshold required to actually slow 
and immobilize nanosystems [34]. In addition, incorporation of PEG into nanosystems also 
reduces the interactions of the systems with other proteins and biomacromolecules. It was 
suggested that the molecular weight of PEG is the determining factor whether PEG will exhibit 
mucoadhesive or mucus-penetrating characteristics and recent findings indicate that when 
densely coated with low molecular weight PEG, nanoparticles avoid adhesive interactions with 
mucus [9,18]. 
To confirm that PEG on the liposomal surface indeed exhibits a mucus-penetrating effect and 




and liposomal preparations was determined. Commercially available pig mucin is commonly 
used as a mucus substitute due to its similarity in the structure and molecular weight to human 
mucus [35]. Based on the fact that the vaginal pH varies in the healthy and infected, as well as 
pre- and post-menopausal women, the experiments were performed both at the conditions of 
healthy vaginal environment (pH 4.6) and those expected to occur during the vaginal bacterial 
infection and post-menopause (pH 7.4). As expected, the PEGylated liposomes did not exhibit 
mucin-binding activity (Table 2). The results indicate a significantly reduced binding efficiency 
at the different pH conditions for the PEGylated liposomes compared to both the conventional 
non-coated liposomes and the 0.1 % (w/v) chitosan-coated liposomes (p < 0.001). 
 
Table 2: Mucin-binding of PEGylated, non-coated and chitosan-coated liposomes (n=3). 
 
The lack of mucin-binding activity coincides with the expected mucus-penetrating properties of 
PEG-modified liposomes [20]. The results indicate that the PEGylated liposomes might be able 
to penetrate the mucus and assure closer contact with the epithelium, thus, enhance mucosal 
delivery of incorporated drug and improve its localized therapeutic outcome.  
 
3.3. In vitro IFN α-2b release 
When evaluating in vitro drug release from topical formulations, including those intended for 
vaginal use, the Franz cell diffusion system is generally considered one of the most appropriate 




therefore we followed the release of liposomally-associated IFN α-2b over 8 hours and compared 
the release to the IFN α-2b release from a control solution. The experimental setup was designed 
to mimic the human conditions; the pH of acceptor medium mimicked the healthy human vaginal 
environment (4.6) and a temperature was set at 37 °C. Further, the experiment was performed in 
the presence of vaginal fluid simulant (VFS), since it is known that the flow, retention, drug 
delivery kinetics and bioactivity of vaginal formulations are influenced by the compounds present 
in the vaginal fluid [13]. The VFS is commonly used in in vitro evaluations of contraceptive and 
prophylactic vaginal drug delivery systems [37]. 
 
Figure 1: A) In vitro IFN α-2b release. Results are expressed as percentage mean ± SD (n = 
3). B) IFN α-2b partitioning after 8 hours. Results are expressed as percentage mean ± SD 
(n = 3). 
Both the PEGylated liposomes and control solution seem to sustain the release of IFN α-2b 
(Figure 1A). Even though the release of liposomally-associated IFN α-2b increased significantly 
(p < 0.001) compared to the control solution after 8 hours, the release was very limited. In a 
preliminary experiment, we have tested three types of membranes, namely cellophane, polyamide 
and cellulose acetate membrane. All three membranes allowed for very limited penetration of 
IFN (data not shown). The pore size of the membrane used in testing should be sufficiently large 
to allow the passage of IFN molecules through; however, it seems that IFN α-2b was mostly 
retained in the membrane, or stayed in the liposomes retained on the membrane surface (Figure 
1B). The significant retention of IFN α-2b in the membrane could be attributed to possible 




2b solution (IntronA®) in the buffer containing polysorbate. Polysorbate is expected to reduce 
the protein adsorption onto the surfaces [38]. Moreover, the concentration of IFN α-2b applied 
onto the diffusion cells was well below the manufacturer’s specification regarding protein 
adsorption onto the membrane. The sustained IFN α-2b release from liposomal formulation was 
in agreement with previously published literature [39]. The release profile observed for our 
system also corresponds to the IFN release profiles from other lipid-based delivery systems [40]. 
A prolonged release is of great importance considering vaginal administration, as reduced 
administration frequency is coherent with better patient compliance and the success of mucosal 
drug delivery is highly dependent on a suitable drug carrier able to remain at the vaginal site over 
prolonged period of time [19].  
 
 
3.4. Ex vivo penetration 
Franz cell diffusion system is also suitable for determination of ex vivo tissue penetration [41-43]. 
Sheep vaginal epithelium is a stratified squamous tissue, similar to that of human, and is used in 
ex vivo testing of vaginal formulations [11,44]. The tissue used in this experiment was from 
pregnant animals [11] and the thickness was 750 µm. In contrast to the strongly sustained release 
of IFN α-2b from liposomes through the artificial membrane, the IFN α-2b penetration through 
the sheep vaginal tissue was prominent, and a distinct increase in IFN α-2b release from the 
PEGylated liposomes was seen (Figure 2A). This demonstrates that the PEGylated liposomal 




solution formulation used as a control. This indicates the potential of PEGylated liposomal 
formulation of IFN α-2b in efficient local vaginal therapy of HPV-infected areas. 
 
Figure 2:  A) Ex vivo IFN α-2b penetration. Results are expressed as percentage mean ± SD 
(n = 3). B) IFN α-2b partitioning after 8 hours ex vivo penetration experiment. Results are 
expressed as percentage mean ± SD (n = 3). 
 
Majority of IFN α-2b from control solution appeared to be retained within or on top of the tissue 
and only a minor amount of drug was able to penetrate through the tissue after 8 hours (Figure 
2B). This limitation of the IFN α-2b in solution form, not in delivery system, is the reason that 
the current IFN α-2b therapy involves direct injections in the affected lesions and is limited by 
both the patient acceptance and efficacy [1]. 
 
3.5. Stability 
Very early work on lipid-based formulations for interferons suggested that the formulations 
remain stable over a period of at least 1 month [45]. It is known that the physical and chemical 
properties of the environment and the presence of semen, might affect the stability and 
performance of the drug delivery system destined for the administration at the vaginal site [15]. 
The composition, volume, pH and rheological properties of vaginal fluids are affected by the age, 
the menstrual cycle or sexual arousal. Some studies suggest that on average 0.5 – 0.75 g of 




increase the acidic pH (4-5) to levels closer to neutral range, which might also affect the stability 
and performance of some vaginal drug delivery systems. The average volume of human ejaculate 
is found to be 3.4 mL [15]; it is expected that the effect of the semen presence on the vaginal pH 
can last for several hours [46]. 
Table 3: Stability of PEGylated liposomes containing IFN α-2b (n=3). 
 
PEGylated liposomes were diluted 1:10 (v/v) with VFS and 1:1 (v/v) with semen fluid simulant 
to determine possible IFN α-2b leakage from the delivery system once exposed to the vaginal 
environment. An incubation time of 2 hours was selected as an appropriate challenge. Only a 
minor leakage of 5.1 % IFN α-2b was detected after 2 hours, indicating the stability of PEGylated 
liposomes in a simulated vaginal environment and in the presence of semen fluid simulant (Table 
3). Considering the high drug load in PEGylated liposomes, the leakage can be considered 
negligible. 
 
We have proven ex vivo that the mucus-penetrating liposomes can assure superior drug 
penetration. However, one has to consider that the retention time at vaginal site might be 
insufficient to assure that an adequate amount of drug can actually penetrate the mucus due to 
rather rapid clearance of foreign particles by the vaginal discharge. Therefore, it might be that 
both mucoadhesive and mucus-penetrating properties of vaginal delivery systems hold promise in 
improved vaginal drug delivery. Very recently, the approach based on combining both the 
mucoadhesive and mucus-penetrating properties within the single delivery system has been 




with the vaginal epithelium and assure penetration of drug in the deeper epithelial layers, in vivo 
testing in infected animals would be required.  
 
4. Conclusions 
Our findings suggest a lack of interactions between mucin and PEGylated liposomes confirming 
the mucus-penetrating properties of PEG. The ability of the IFN α-2b entrapped in PEGylated 
liposomes to penetrate through the vaginal tissue was distinctively increased for the PEGylated 
liposomal formulations as compared to IFN α-2b in solution. This indicates that PEGylated 
liposomal formulation represents a promising approach to assure drug delivery in the close 
proximity to the vaginal epithelium for therapeutic use. Furthermore, the PEGylated liposomes 
were shown to be stable in the simulated vaginal environment.  
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Figure 2: A) Ex vivo IFN α-2b penetration. Results are expressed as percentage mean ± SD 
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Table 1: Characteristics of PEGylated liposomes containing IFN α-2b (n = 3). 
 Vesicle size (nm) PI* Zeta potential (mV) Entrapment (%) 
PEGylated liposomes 
containing IFN α-2b 
181 ± 8 0.129 - 13.33 ± 0.81 81 ± 10 
*Polydispersity index 
 
Table 2: Mucin-binding of PEGylated, non-coated and chitosan-coated liposomes (n = 3). 
Liposomal samples* 
Mucin-binding (%) 
pH 7.4 pH 4.6 
PEGylated  3.8 ± 2.6 7.0 ± 14.6 
Non-coated  22.1 ± 3.3 36.0 ± 3.2 












* Polydispersity index, 
a 
Freshly made liposomal formulation, 
b
 After storage in a fridge (4 °C) 
for 1 month, 
c





Size Zeta potential Entrapment 
(nm) PI* (mV) (%) 
Fresh a 181 ± 8 0.129 - 13.33 ± 0.81 81.0 ± 9.8 
After storage b  182 ± 7 0.098 - 13.00 ± 0.45 - 








Schematic drawing of PEGylated liposome and the IFN α-2b partitioning after 8 hours ex vivo 
penetration experiment. 
*IFN α-2b in Intron A buffer 
 
 
 
